English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical results for LP-184, demonstrating synergy with checkpoint inhibitors and the ability to resensitize tumors non-responsive to Anti-PD1 therapies. Key findings include:
1. LP-184 potentiates anti-PD1 response in a mouse model of triple negative breast cancer (TNBC) resistant to immunotherapy.
2. It can transform 'cold' tumors into 'hot' tumors by modulating T cell activity and inducing replication stress response defects.
3. LP-184 reshapes the tumor microenvironment by reducing M2 macrophages associated with tumor drug resistance.
4. Combined with anti-PD1, LP-184 showed greater anti-tumor response than monotherapies in mouse TNBC tumors.
LP-184 is currently in a Phase 1 trial for advanced recurrent solid tumors. This research supports Lantern's AI-driven hypothesis on LP-184's potential to synergize with PD1 and PDL1 drugs, potentially improving cancer treatment outcomes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
Translate
Report
2359 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    1666Followers
    93Following
    13KVisitors
    Follow